Search results for "Mace"

showing 10 items of 4713 documents

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

2011

Introduction: The use of monoclonal antibodies is one of the strategies for targeting the specific key points of the main pathways of cancer growth and survival, but only a few antibodies have offered a clear clinical benefit in the treatment of non-haematological malignancies. Areas covered: This review summarizes the general properties of monoclonal antibodies, including structure, nomenclature and production techniques. The antibodies approved for use in clinical practice for the treatment of non-haematological tumors and those antibodies still being developed in this setting are briefly described. The types of antibody fragments are also reported. Expert opinion: Monoclonal antibodies w…

medicine.drug_classSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryMonoclonal antibodyAntibody fragmentsNeoplasm ProteinNeoplasmsDrug DiscoveryImmunoglobulin FragmentmedicineAnimalsHumansImmunoglobulin FragmentsAnti-EGFRPharmacologyChemotherapyMonoclonal antibodiebiologybusiness.industryAnimalDrug Discovery3003 Pharmaceutical ScienceAnti-VEGFCancerAntibodies MonoclonalImmunotherapymedicine.diseaseAntibody fragmentNeoplasm ProteinsAnti-HER2Clinical PracticeTreatment OutcomeExpert opinionImmunologybiology.proteinNeoplasmMonoclonal antibodiesImmunotherapyAnti-EGFR; Anti-HER2; Anti-VEGF; Antibody fragments; Monoclonal antibodiesAntibodybusinessHuman
researchProduct

Synthesis, biological evaluation, and structure-activity relationship study of novel cytotoxic aza-caffeic acid derivatives.

2010

Abstract Three series of aza-caffeic acid derivatives with different linkers were designed and synthesized. Each of the synthesized derivatives was then used in cytotoxicity screening on either 8 or 12 human cancer cell lines. The structure–activity relationships on three structural regions A, B, and C are analyzed in detail, indicating that a nine bond linker B, containing a piperazine unit, is the most favorable linker leading to the generation of molecules with potent cytotoxicities. Compound ( E )-1-(4-(3,4-dichlorobenzyl)piperazin-1-yl)-3-(4-(4-ethoxybenzyloxy)-3,5-dimethoxyphenyl)prop-2-en-1-one ( 80 ) exhibited the most significant and selective cytotoxicity to KB, BEL7404, K562, and…

medicine.drug_classStereochemistryClinical BiochemistryPharmaceutical ScienceCarboxamideBiochemistryChemical synthesischemistry.chemical_compoundStructure-Activity RelationshipCaffeic AcidsCell Line TumorDrug DiscoverymedicineCaffeic acidStructure–activity relationshipHumansCytotoxicityCaffeic acid phenethyl esterMolecular BiologyAza CompoundsChemistryOrganic ChemistryFlow CytometryPiperazineBiochemistryMolecular MedicineLinkerBioorganicmedicinal chemistry
researchProduct

Paroxetine Administration Affects Microbiota and Bile Acid Levels in Mice.

2020

Recent interest in the role of microbiota in health and disease has implicated gut microbiota dysbiosis in psychiatric disorders including major depressive disorder. Several antidepressant drugs that belong to the class of selective serotonin reuptake inhibitors have been found to display antimicrobial activities. In fact, one of the first antidepressants discovered serendipitously in the 1950s, the monoamine-oxidase inhibitor Iproniazid, was a drug used for the treatment of tuberculosis. In the current study we chronically treated DBA/2J mice for 2 weeks with paroxetine, a selective serotonin reuptake inhibitor, and collected fecal pellets as a proxy for the gut microbiota from the animals…

medicine.drug_classlcsh:RC435-571Serotonin reuptake inhibitorClinical SciencesmicrobiomeGut floraPharmacology03 medical and health sciences0302 clinical medicineRare Diseaseslcsh:PsychiatrymedicinePsychologyMicrobiomeCancerOriginal ResearchPsychiatrybile acidsantidepressantbiologyBile acidbusiness.industryDepressionbiology.organism_classificationmedicine.diseaseParoxetinemetabolomics030227 psychiatryColo-Rectal CancerPsychiatry and Mental healthMental HealthGood Health and Well Being5.1 PharmaceuticalsPublic Health and Health ServicesAntidepressantDevelopment of treatments and therapeutic interventionsbusinessDigestive DiseasesDysbiosis030217 neurology & neurosurgeryBehavioural despair testmedicine.drugparoxetineFrontiers in psychiatry
researchProduct

General quality of life of patients with acne vulgaris before and after performing selected cosmetological treatments

2017

Background Achieving a satisfying quality of life for a patient by applying individually matched therapy is, simultaneously, a great challenge and a priority for contemporary medicine. Patients with visible dermatological ailments are particularly susceptible to reduction in the general quality of life. Among the dermatological diseases, acne causes considerable reduction in the quality of life and changes in self-perception that lead to the worsening of a patient's mental condition, including depression and suicidal thoughts. As a result, difficulties in contact with loved ones, as well as social and professional problems are observed, which show that acne is not a somatic problem alone. T…

medicine.medical_specialtyActivities of daily livingAlternative medicineMedicine (miscellaneous)cosmetological treatments030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeacne vulgarisMedicine030212 general & internal medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)AcneDepression (differential diagnoses)Original Researchbusiness.industryHealth PolicyDermatology Life Quality IndexPsychodermatologymedicine.diseaseDermatologyMesotherapyquality of lifebusinessSocial Sciences (miscellaneous)Patient Preference and Adherence
researchProduct

Medication adherence and persistence in type 2 diabetes mellitus: perspectives of patients, physicians and pharmacists on the Spanish health care sys…

2017

Elena Labrador Barba,1 Marta Rodríguez de Miguel,1 Antonio Hernández-Mijares,2,3 Francisco Javier Alonso-Moreno,4 Maria Luisa Orera Peña,1 Susana Aceituno,5 María José Faus Dader6 1Department of Medicine, Mylan, Madrid, 2Department of Endocrinology and Nutrition, Doctor Peset University Hospital, Valencia, 3Department of Medicine, University of Valencia, Valencia, 4Department for Primary Health Care, Centro de Salud Sillería, Toledo, 5Outcomes’10, Castellon, 6Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Granada, Granada, Spain Objective: A good relationship between diabetes pa…

medicine.medical_specialtyActivities of daily livingtype 2 diabetes mellitusMedicine (miscellaneous)030209 endocrinology & metabolismLikert scale03 medical and health sciences0302 clinical medicineDiabetes mellitusHealth caremedicine030212 general & internal medicineadherenceAdverse effectPharmacology Toxicology and Pharmaceutics (miscellaneous)Original Researchbusiness.industryHealth PolicyfactorsType 2 Diabetes Mellituspersistencemedicine.diseaseClinical pharmacyPatient Preference and AdherenceFamily medicinestrategiesObservational studybusinessSocial Sciences (miscellaneous)Patient preference and adherence
researchProduct

How to select a biosimilar

2013

In the past few years biosimilars have penetrated the market following the expiry of patents of originator variants. This offers the opportunity to apply high-tech protein products at a lower cost. In contrast to small-molecule generics, clinicians and pharmacists have found it difficult to judge the efficacy and safety profiles of complex protein products. In recent years, the European Medicines Agency (EMA) has gained knowledge on assessing comparability between biosimilars and originator products in scientific and legal areas. This article provides an overview of an extensive set of 31 previously drawn biosimilar selection criteria and describes how several of these criteria are covered …

medicine.medical_specialtyActuarial scienceComplex proteinbusiness.industryAgency (sociology)ComparabilityAlternative medicinemedicineLower costBiosimilarGeneral Pharmacology Toxicology and Pharmaceuticsbusiness
researchProduct

Reduced serum protease activity in Complex Regional Pain Syndrome: The impact of angiotensin-converting enzyme and carboxypeptidases.

2021

Complex Regional Pain Syndrome (CRPS) occurs in about 2% of patients after fracture of the limbs. In an earlier clinical study with 102 probands we have shown that the serum protease network in CRPS might be less effective. Based on these results we hypothesized that angiotensin-converting enzyme (ACE) and carboxypeptidase N (CPN) activity contribute to the differences of labeled bradykinin (DBK) degradation by patients' sera. Details of the enzymatic processes remained however unclear. The contributions of ACE and CPN in the serum degradation of DBK were studied using specific inhibitors. CPN1-ELISA was performed in serum. It was confirmed that the majority of DBK was degraded by ACE and C…

medicine.medical_specialtyAngiotensinsmedicine.medical_treatmentClinical BiochemistryPharmaceutical ScienceBradykininCarboxypeptidasesBradykininAnalytical Chemistrychemistry.chemical_compoundInternal medicineDrug DiscoverymedicineHumansSpectroscopyProteasebiologyCaptoprilAngiotensin-converting enzymemedicine.diseaseBlood proteinsCarboxypeptidasePathophysiologyEndocrinologyComplex regional pain syndromechemistrybiology.proteinFemaleComplex Regional Pain Syndromesmedicine.drugPeptide HydrolasesJournal of pharmaceutical and biomedical analysis
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct

Mild cognitive impairment: A systematic review

2007

MCI is a nosological entity proposed as an intermediate state between normal aging and dementia. The syndrome can be divided into two broad subtypes: amnestic MCI ( aMCI) characterized by reduced memory, and non- amnestic MCI ( naMCI) in which other cognitive functions rather than memory are mostly impaired. aMCI seems to represent an early stage of AD, while the outcomes of the naMCI subtypes appear more heterogeneous - including vascular dementia, frontotemporal dementia or dementia with Lewy bodies- but this aspect is still under debate. MCI in fact represents a condition with multiple sources of heterogeneity, including clinical presentation, etiology, and prognosis. To improve classifi…

medicine.medical_specialtyApolipoprotein E4Neuropsychological TestsSeverity of Illness Indexbehavioral disciplines and activitiesPhysical medicine and rehabilitationNeuroimagingAlzheimer DiseaseFluorodeoxyglucose F18Risk Factorsmental disordersEpidemiologySeverity of illnessmedicineHumansDementiaVascular dementiaapolipoprotein EAlzheimer disease; apolipoprotein E; biomarkers; diagnosis; mild congnitive impairmentMemory Disordersbusiness.industryDementia VascularGeneral NeuroscienceBrainCognitionGeneral Medicinemedicine.diseaseMagnetic Resonance Imagingmild congnitive impairmentdiagnosiPsychiatry and Mental healthClinical PsychologyEtiologybiomarkerSettore MED/26 - NeurologiaRadiopharmaceuticalsGeriatrics and GerontologyCognition DisordersbusinessFrontotemporal dementia
researchProduct

Different mechanism of relaxation induced by aporphine alkaloids in rat uterus.

1993

Abstract We have examined the uterine relaxant action of three aporphine molecules (S-glaucine, S-boldine and R-apomorphine) in two experimental conditions, with and without calcium in the bathing solution, and compared these effects with those obtained with the calcium antagonists verapamil and diltiazem. The present study shows that the alkaloids relax the uterine muscle but with different mechanisms of action. In Ca2+-containing solution all three alkaloids relaxed the uterus previously contracted by KCl or acetylcholine, but in Ca2+-free medium only R-apomorphine was able to relax oxytocin-induced contraction. The calcium antagonists, verapamil and diltiazem, relaxed KCl- or acetylcholi…

medicine.medical_specialtyAporphinesApomorphineMuscle RelaxationPharmaceutical Sciencechemistry.chemical_elementCalciumIn Vitro TechniquesOxytocinUterine contractionPotassium Chloridechemistry.chemical_compoundUterine ContractionInternal medicinemedicineBoldineAnimalsDrug InteractionsDiltiazemAporphineRats WistarPharmacologyCalcium Channel BlockersGlaucineAcetylcholineCulture MediaRatsEndocrinologyMuscle relaxationchemistryBiophysicsVerapamilCalciumFemalemedicine.symptommedicine.drugThe Journal of pharmacy and pharmacology
researchProduct